Developing drug molecules for therapy with carbon monoxide
The use of Carbon Monoxide (CO) as a therapeutic agent has already been tested in human
clinical trials. Pre-clinically, CO gas administration proved beneficial in animal models of …
clinical trials. Pre-clinically, CO gas administration proved beneficial in animal models of …
Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody–cytotoxic drug conjugate
…, LM Crocker, KL Parsons, E Mai, WA Blattler… - Cancer research, 2008 - AACR
HER2 is a validated target in breast cancer therapy. Two drugs are currently approved for
HER2-positive breast cancer: trastuzumab (Herceptin), introduced in 1998, and lapatinib (…
HER2-positive breast cancer: trastuzumab (Herceptin), introduced in 1998, and lapatinib (…
Antibody-maytansinoid conjugates are activated in targeted cancer cells by lysosomal degradation and linker-dependent intracellular processing
…, K Hoffman, RJ Lutz, VS Goldmacher, WA Blättler - Cancer research, 2006 - AACR
Antibody-drug conjugates are targeted anticancer agents consisting of a cytotoxic drug
covalently linked to a monoclonal antibody for tumor antigen–specific activity. Once bound to the …
covalently linked to a monoclonal antibody for tumor antigen–specific activity. Once bound to the …
Antibody-drug conjugates designed to eradicate tumors with homogeneous and heterogeneous expression of the target antigen
…, SJ Phinney, BA Leece, T Chittenden, WA Blättler… - Cancer research, 2006 - AACR
Conjugates of the anti-CanAg humanized monoclonal antibody huC242 with the
microtubule-formation inhibitor DM1 (a maytansinoid), or with the DNA alkylator DC1 (a CC1065 …
microtubule-formation inhibitor DM1 (a maytansinoid), or with the DNA alkylator DC1 (a CC1065 …
Semisynthetic maytansine analogues for the targeted treatment of cancer
…, RJ Lutz, R Zhao, L Wang, WA Blättler… - Journal of medicinal …, 2006 - ACS Publications
Maytansine, a highly cytotoxic natural product, failed as an anticancer agent in human
clinical trials because of unacceptable systemic toxicity. The potent cell killing ability of …
clinical trials because of unacceptable systemic toxicity. The potent cell killing ability of …
Structural characterization of the maytansinoid–monoclonal antibody immunoconjugate, huN901–DM1, by mass spectrometry
L Wang, G Amphlett, WA Blättler, JM Lambert… - Protein …, 2005 - Wiley Online Library
Immunoconjugates are being explored as novel cancer therapies with the promise of target‐specific
drug delivery. The immunoconjugate, huN901–DM1, composed of the humanized …
drug delivery. The immunoconjugate, huN901–DM1, composed of the humanized …
An anti-insulin-like growth factor I receptor antibody that is a potent inhibitor of cancer cell proliferation
…, LM Garrett, KM Connors, XM Zhou, WA Blättler… - Cancer research, 2003 - AACR
An antagonistic monoclonal antibody, designated EM164, has been developed which binds
specifically to the human insulin-like growth factor I receptor (IGF-IR) and inhibits the …
specifically to the human insulin-like growth factor I receptor (IGF-IR) and inhibits the …
Eradication of large colon tumor xenografts by targeted delivery of maytansinoids.
…, JM Lambert, WA Blättler… - Proceedings of the …, 1996 - National Acad Sciences
The maytansinoid drug DM1 is 100- to 1000-fold more cytotoxic than anticancer drugs that
are currently in clinical use. The immunoconjugate C242-DM1 was prepared by conjugating …
are currently in clinical use. The immunoconjugate C242-DM1 was prepared by conjugating …
Analysis of the composition of immunoconjugates using size‐exclusion chromatography coupled to mass spectrometry
AC Lazar, L Wang, WA Blättler… - … Journal Devoted to …, 2005 - Wiley Online Library
Recombinant monoclonal antibody drug products play an increasingly important role in the
treatment of various diseases. Antibodies are large, multi‐chain proteins and antibody …
treatment of various diseases. Antibodies are large, multi‐chain proteins and antibody …
Identification of domains of the insulin-like growth factor I receptor that are required for protection from apoptosis
…, S Lehar, GI Evan, R Baserga, WA Blättler - … and cellular biology, 1997 - Am Soc Microbiol
Using a series of insulin-like growth factor I (IGF-I) receptor mutants, we have attempted to
define domains required for transmitting the antiapoptotic signal from the receptor and to …
define domains required for transmitting the antiapoptotic signal from the receptor and to …